PEDRO ENRIQUE DORLHIAC LLACER

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Autor: CERVANTES, Francisco ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • conferenceObject
    Effect of continued imatinib (IM) in pts with detectable BCR-ABL after >= 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.
    (2014) SPECTOR, Nelson; CLEMENTINO, Nelma Cristina D.; DORLHIAC-LLACER, Pedro Enrique; LEBER, Brian; HUGHES, Timothy P.; CERVANTES, Francisco; SCHWARER, Anthony P.; FORREST, Donna L.; KAMEL-REID, Suzanne; BENDIT, Israel; ACHARYA, Sandip; COLLINS, LaTonya; DALAI, Darshan; LIPTON, Jeffrey H.
  • article 82 Citação(ões) na Scopus
    Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
    (2014) HUGHES, Timothy P.; LIPTON, Jeffrey H.; SPECTOR, Nelson; CERVANTES, Francisco; PASQUINI, Ricardo; CLEMENTINO, Nelma Cristina D.; LLACER, Pedro Enrique Dorlhiac; SCHWARER, Anthony P.; MAHON, Francois-Xavier; REA, Delphine; BRANFORD, Susan; PURKAYASTHA, Das; COLLINS, LaTonya; SZCZUDLO, Tomasz; LEBER, Brian
    Patients in complete cytogenetic response (CCyR) with detectable BCR-ABL1 after >= 2 years on imatinib were randomized to nilotinib (400 mg twice daily, n = 104) or continued imatinib (n = 103) in the Evaluating Nilotinib Efficacy and Safety in clinical Trials-Complete Molecular Response (ENESTcmr) trial. By 1 and 2 years, confirmed undetectable BCR-ABL1 was achieved by 12.5% vs 5.8% (P = .108) and 22.1% vs 8.7% of patients in the nilotinib and imatinib arms, respectively (P = .0087). Among patients without molecular response 4.5 (BCR-ABL1(IS) <= 0.0032%; MR4.5) and those without major molecular response at study start, MR4.5 by 2 years was achieved by 42.9% vs 20.8% and 29.2% vs 3.6% of patients in the nilotinib and imatinib arms, respectively. No patient in the nilotinib arm lost CCyR, vs 3 in the imatinib arm. Adverse events were more common in the nilotinib arm, as expected with the introduction of a new drug vs remaining on a well-tolerated drug. The safety profile of nilotinib was consistent with other reported studies. In summary, switching to nilotinib enabled more patients with chronic myeloid leukemia in chronic phase (CML-CP) to sustain lower levels of disease burden vs remaining on imatinib. This trial was registered at www. clinicaltrials.gov as # NCT00760877.
  • conferenceObject
    Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up
    (2012) LIPTON, Jeffrey Howard; HUGHES, Timothy P.; LEBER, Brian; SOUZA, Carmino De; DORLHIAC-LLACER, Pedro E.; STEEGMANN, Juan Luis; GUERCI-BRESLER, Agnes; SCHWARER, Anthony P.; CERVANTES, Francisco; REYNOLDS, John; COLLINS, LaTonya R.; SZCZUDLO, Tomasz K.; SPECTOR, Nelson